Overcoming EGFR monotherapy resistance may require patient-specific signaling signature (PaSSS) analyses to develop PaSSS-based drug combinations suitable for altered signaling networks in HNSCC [135]. Here, EGFR is linked to head and neck squamous cell carcinoma.